View More Recent Stories

Jan 19, 2021 03:00AM Intravacc announces completion of formulation and manufacturing process development of PRV-101 vaccine candidate for Provention Bio
Jan 6, 2021 04:05PM Provention Bio to Participate in the H.C. Wainwright Virtual BioConnect Conference
Jan 4, 2021 07:07AM Provention Bio Inc. (PRVB) Announces U.S. FDA Filing of BLA and Priority Review for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals
Jan 4, 2021 07:00AM Provention Bio Announces U.S. FDA Filing of a Biologics License Application (BLA) and Priority Review for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals
Dec 21, 2020 07:30AM Provention Bio Announces Addition to NASDAQ Biotechnology Index
Dec 15, 2020 07:31AM Provention Bio Inc. (PRVB) Initiates First-in-Human Study of Coxsackievirus B Vaccine Candidate PRV-101
Dec 15, 2020 07:30AM Provention Bio Initiates First-in-Human Study of Coxsackievirus B Vaccine Candidate PRV-101
Dec 8, 2020 08:55AM JDRF Launches First Mass Screening Program for Early-Stage Type 1 Diabetes (T1D) Detection
Nov 11, 2020 07:30AM Provention Bio to Present at the Stifel Virtual Healthcare Conference
Nov 5, 2020 07:00AM Provention Bio Reports Third Quarter 2020 Financial Results and Provides Business Update
Nov 2, 2020 07:40AM Provention Bio (PRVB) Completes Rolling Submission of BLA for Teplizumab for Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals
Nov 2, 2020 07:30AM Provention Bio Completes Rolling Submission of the Biologics License Application (BLA) for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals
Oct 29, 2020 07:30AM Provention Bio to Report Third Quarter 2020 Financial Results and Host Conference Call on Thursday, November 5, 2020
Oct 1, 2020 07:30AM Provention Bio Announces National Effort to Redefine Patient Care in Type 1 Diabetes (T1D)
Jul 1, 2019 07:34AM Intrexon (XON) Subsidiary ActoBio Therapeutics Inc. Advances AG019 to Next Stage of Phase Ib/IIa Clinical Study
Jul 1, 2019 07:30AM ActoBio Therapeutics™ Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of Type 1 Diabetes
Nov 28, 2018 07:33AM Provention Bio Joins the C-Path Type 1 Diabetes (T1D) Consortium
Nov 5, 2018 09:04AM Amgen (AMGN), Provention Bio (PRVB) Announce Co-Development Collaboration In Celiac Disease
Nov 5, 2018 09:00AM Amgen And Provention Bio Announce Co-Development Collaboration In Celiac Disease
View More Recent Stories